The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Paediatric Rheumatology International Trials Organisation (PRINTO)

Research output: Contribution to journalArticle

Abstract

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis, and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

Original languageEnglish
Pages (from-to)395-402
Number of pages8
JournalRheumatology International
Volume38
Issue numberSuppl 1
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Juvenile Arthritis
Psychometrics
Reproducibility of Results
Parents
Arthritis
Reading
Healthy Volunteers

Keywords

  • Adolescent
  • Age of Onset
  • Arthritis, Juvenile/diagnosis
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Cultural Characteristics
  • Disability Evaluation
  • Female
  • Health Status
  • Humans
  • Male
  • Parents/psychology
  • Patient Reported Outcome Measures
  • Patients/psychology
  • Predictive Value of Tests
  • Prognosis
  • Psychometrics
  • Quality of Life
  • Reproducibility of Results
  • Rheumatology/methods
  • Translating
  • Turkey

Cite this

The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). / Paediatric Rheumatology International Trials Organisation (PRINTO).

In: Rheumatology International, Vol. 38, No. Suppl 1, 04.2018, p. 395-402.

Research output: Contribution to journalArticle

Paediatric Rheumatology International Trials Organisation (PRINTO) 2018, 'The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)', Rheumatology International, vol. 38, no. Suppl 1, pp. 395-402. https://doi.org/10.1007/s00296-018-3982-8
Paediatric Rheumatology International Trials Organisation (PRINTO). / The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). In: Rheumatology International. 2018 ; Vol. 38, No. Suppl 1. pp. 395-402.
@article{26cf59f809874cee836facd3ffe1a11b,
title = "The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)",
abstract = "The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 466 JIA patients (13.7{\%} systemic, 40.6{\%} oligoarticular, 22.5{\%} RF negative poly-arthritis, and 23.2{\%} other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.",
keywords = "Adolescent, Age of Onset, Arthritis, Juvenile/diagnosis, Case-Control Studies, Child, Child, Preschool, Cultural Characteristics, Disability Evaluation, Female, Health Status, Humans, Male, Parents/psychology, Patient Reported Outcome Measures, Patients/psychology, Predictive Value of Tests, Prognosis, Psychometrics, Quality of Life, Reproducibility of Results, Rheumatology/methods, Translating, Turkey",
author = "{Paediatric Rheumatology International Trials Organisation (PRINTO)} and Erkan Demirkaya and Seza Ozen and Betul Sozeri and Ayaz, {Nuray Aktay} and Ozgur Kasapcopur and Erbil Unsal and Makay, {Balahan Bora} and Kenan Barut and Fidanci, {Berna Eren} and Dogan Simsek and Mustafa Cakan and Alessandro Consolaro and Francesca Bovis and Nicolino Ruperto",
year = "2018",
month = "4",
doi = "10.1007/s00296-018-3982-8",
language = "English",
volume = "38",
pages = "395--402",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "Suppl 1",

}

TY - JOUR

T1 - The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

AU - Paediatric Rheumatology International Trials Organisation (PRINTO)

AU - Demirkaya, Erkan

AU - Ozen, Seza

AU - Sozeri, Betul

AU - Ayaz, Nuray Aktay

AU - Kasapcopur, Ozgur

AU - Unsal, Erbil

AU - Makay, Balahan Bora

AU - Barut, Kenan

AU - Fidanci, Berna Eren

AU - Simsek, Dogan

AU - Cakan, Mustafa

AU - Consolaro, Alessandro

AU - Bovis, Francesca

AU - Ruperto, Nicolino

PY - 2018/4

Y1 - 2018/4

N2 - The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis, and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

AB - The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis, and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

KW - Adolescent

KW - Age of Onset

KW - Arthritis, Juvenile/diagnosis

KW - Case-Control Studies

KW - Child

KW - Child, Preschool

KW - Cultural Characteristics

KW - Disability Evaluation

KW - Female

KW - Health Status

KW - Humans

KW - Male

KW - Parents/psychology

KW - Patient Reported Outcome Measures

KW - Patients/psychology

KW - Predictive Value of Tests

KW - Prognosis

KW - Psychometrics

KW - Quality of Life

KW - Reproducibility of Results

KW - Rheumatology/methods

KW - Translating

KW - Turkey

U2 - 10.1007/s00296-018-3982-8

DO - 10.1007/s00296-018-3982-8

M3 - Article

VL - 38

SP - 395

EP - 402

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - Suppl 1

ER -